PAR paradigm biopharmaceuticals limited..

MOZZ OARSI 2023 - NOTES, page-22

  1. 10,383 Posts.
    lightbulb Created with Sketch. 1414
    I'm not sure it's quite that simple and my impression is the FDA is still to land on what's required for DMOAD status.

    The thought leaders appear to have identified preferred surrogate SF biomarkers

    Any thoughts on why they didn't previous disclosure "insufficient numbers of results above LLQ" for CTX-II, C2C, IL-1B and whether this then could impact 6 month results?




 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
42.0¢
Change
0.010(2.44%)
Mkt cap ! $166.9M
Open High Low Value Volume
40.0¢ 42.0¢ 40.0¢ $168.2K 411.3K

Buyers (Bids)

No. Vol. Price($)
1 3500 41.0¢
 

Sellers (Offers)

Price($) Vol. No.
42.0¢ 50665 2
View Market Depth
Last trade - 16.11pm 18/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.